



The Manager
Company Announcements
Australian Stock Exchange
4th Floor
20 Bridge Street
SYDNEY NSW 2000

24 March 2005

Dear Sir,

RESONANCE HEALTH GROUP AND DCA GROUP TO COOPERATE ON COMMERCIAL LAUNCH OF FERRISCAN TEST

Australia. 23 March 2005. Resonance Health (ASX: RHT) today confirmed that it has entered into an Agreement with its subsidiary Inner Vision Biometrics Pty Ltd (“IVB”) and Australia’s largest diagnostic imaging group, the DCA Group (ASX: DVC) to launch and co-market IVB’s FerriScan technology for the non-invasive measurement of iron levels in the liver.

The DCA Group’s I-Med/MIA Network is the largest diagnostic imaging group outside of the USA. It currently has 47 MRI centres located in Australia and the United Kingdom. The I-MED/MIA Network and IVB will cooperate in the staged launch of the FerriScan test in Australia and potentially the United Kingdom.

FerriScan is a novel non-invasive test, developed by IVB, which utilises magnetic resonance imaging (MRI) technology to accurately measure iron levels in the liver. Iron overload diseases are amongst the most common genetic disorders and are a significant cause of mortality around the world.

Preparations for the first stage in the collaboration for the introduction of FerriScan in selected locations are well progressed, with commercial sales of the test expected to commence in March 2005.

Key components of the agreement include:

- The FerriScan test will be available through selected sites in the I-Med/MIA Network.
- I-Med/MIA will be the exclusive commercial radiology partner of IVB in Australia and the UK with the exception of IVB’s existing research and commercial arrangements in Australia and the UK.
- IVB and I-Med/MIA will collaborate to secure public and private reimbursement for the combination of the MRI and FerriScan test in Australia and the UK.

“The collaboration with the I-Med/MIA Network is the first step in the planned global roll out of FerriScan,” said Dr James Williams, CEO of Inner Vision Biometrics.

“The company’s strategy is to use the established referral base and marketing capabilities of leading radiology groups to maximise exposure and uptake of our ground breaking technology. As one of Australia’s leading diagnostic imaging companies, the I-Med/MIA Network represents an ideal partner through which to demonstrate the clinical and commercial value of FerriScan to the global market.”

Additionally, an integral part of the commercial arrangement is DCA’s ability to take up the option of building an equity stake of up to 10% in Resonance Health Ltd (subject to milestones and other conditions).

About DCA Group

The DCA Group is one of Australia 's leading health companies and, following its recent merger with the MIA Group, has a major focus in diagnostic imaging (radiology and nuclear medicine) and radiation oncology services.

These services are provided by over 250 doctors and more than 2400 medical and support staff. The DCA Group’s diagnostic imaging division operates a comprehensive network of over 365 clinics in Australia and the UK, generating annual revenues of around \$800 million.

About Resonance

Resonance Health (formerly GEO2 Limited) acquired a controlling interest in the FerriScan technology in November 2003. On 1st March 2005, Resonance Health announced that, subject to it receiving required regulatory and shareholder approvals, it had agreed terms with minority shareholders of IVB to acquire 100% of the outstanding shares in IVB. As a result of this transaction, Resonance Health will receive 100% of any potential revenue streams arising from the commercialization of IVB’s FerriScan technology and intellectual property. The technology taps a strong and growing demand worldwide for new non invasive diagnostic and monitoring techniques.

About FerriScan

The importance of early diagnosis and the ability to accurately monitor iron concentration within the liver is crucial to the management of chronic iron disorders and the long term health of the patient.

The FerriScan test assists in the diagnosis and monitoring of iron overload diseases without the need for invasive procedures. FerriScan is aimed primarily at detecting iron overload which leads to iron toxicity and liver damage and then monitoring the effectiveness of ongoing treatment. In addition to haemochromatosis, Ferriscan has immediate application for patients suffering from several disorders of the blood (e.g. thalassaemia), and may also in be helpful in the management of patients with hepatitis and adult onset diabetes.

Media and Investor Relations	Resonance Health
Rebecca Christie Buchan Consulting Pty Ltd SYDNEY: T - +61 2 9293 2836 F - +61 2 9293 2828 M - 0417 382 391 Rchristie@bcg.com.au	Tony Fitzgerald Executive Director, Resonance Health Ltd T - +61 8 9389 5933 M - 0418 903 647; or Dr James Williams CEO, Inner Vision Biometrics Pty Ltd T - +61 9286 5300 M 0409 050 519 Email: jamesw@ferriscan.com